CD1d deficiency inhibits the development of abdominal aortic aneurysms in LDL receptor deficient mice

PLoS One. 2018 Jan 18;13(1):e0190962. doi: 10.1371/journal.pone.0190962. eCollection 2018.

Abstract

An abdominal aortic aneurysm (AAA) is a dilatation of the abdominal aorta leading to serious complications and mostly to death. AAA development is associated with an accumulation of inflammatory cells in the aorta including NKT cells. An important factor in promoting the recruitment of these inflammatory cells into tissues and thereby contributing to the development of AAA is angiotensin II (Ang II). We demonstrate that a deficiency in CD1d dependent NKT cells under hyperlipidemic conditions (LDLr-/-CD1d-/- mice) results in a strong decline in the severity of angiotensin II induced aneurysm formation when compared with LDLr-/- mice. In addition, we show that Ang II amplifies the activation of NKT cells both in vivo and in vitro. We also provide evidence that type I NKT cells contribute to AAA development by inducing the expression of matrix degrading enzymes in vSMCs and macrophages, and by cytokine dependently decreasing vSMC viability. Altogether, these data prove that CD1d-dependent NKT cells contribute to AAA development in the Ang II-mediated aneurysm model by enhancing aortic degradation, establishing that therapeutic applications which target NKT cells can be a successful way to prevent AAA development.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / administration & dosage
  • Animals
  • Antigens, CD1d / genetics*
  • Aortic Aneurysm, Abdominal / prevention & control*
  • Apoptosis / immunology
  • Flow Cytometry
  • Lymphocyte Activation
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Muscle, Smooth, Vascular / immunology
  • Muscle, Smooth, Vascular / pathology
  • NIH 3T3 Cells
  • Natural Killer T-Cells / immunology
  • Real-Time Polymerase Chain Reaction
  • Receptors, LDL / genetics*

Substances

  • Antigens, CD1d
  • Cd1d1 protein, mouse
  • Receptors, LDL
  • Angiotensin II

Grants and funding

This study was funded by Hartstichting, with the following grants: 2007T039 (Dr. Gijs H.M. van Puijvelde); 2008B048 (Ph.D. Amanda C. Foks); 2012T083 (Ph.D. Ilze Bot). Louis Boon, employed by Bioceros BV, Utrecht, The Netherlands, supported this study in the form of providing us with neutralizing α-IFNγ, α-IL4 and α-IL10 antibodies and did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.